[ORGANIZATION]
Viking Therapeutics
Featured in 4 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
270 clusters · 979 sources · last updated
Latest: GLP-1 obesity medications linked to nutritional risks and variable efficacy
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr
Also covered in
-
Viking Therapeutics reports positive Phase 2 obesity drug data
[BUSINESS] · 4 sources ·
-
Pharmaceutical sector sees growth in GLP-1 drugs and production technology
[BUSINESS] · 4 sources ·
-
Viking Therapeutics Beats Q2 Earnings Estimates, Highlights Progress on Obesity Drug VK2735
[BUSINESS] · 4 sources ·